SCHEMBL6286861

SCHEMBL6286861

CC(C)c1cnc(NC(=O)Nc2ccc3cn[nH]c3c2)s1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 4/20 0.60
CDK5 Q00535 4/20 0.60
CCNE1 P24864 3/20 0.60
ALDH1A1 P00352 6/20 0.55
MAPT P10636 4/20 0.51
KDM4E B2RXH2 4/20 0.51
MEN1 O00255 1/20 0.51
F2 P00734 1/20 0.51
KMT2A Q03164 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
RPS6KB1 P23443 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
HIF1A Q16665 1/20 0.48
PHLPP2 Q6ZVD8 1/20 0.48
HSD17B10 Q99714 1/20 0.48
MAP4K4 O95819 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6282877 0.84 CDK2 (0.60) CDK2CDK5CCNE1ALDH1A1MAPT
SCHEMBL6286071 0.80 CDK2 (0.60) CDK2CDK5CCNE1ALDH1A1MAPT
SCHEMBL5784478 0.78 CDK5 (0.66) CDK2CDK5CCNE1ALDH1A1MAPT
SCHEMBL6286119 0.78 CDK2 (0.67) CDK2CDK5CCNE1ALDH1A1MAPT
SCHEMBL6286656 0.78 CDK2 (0.60) CDK2CDK5CCNE1ALDH1A1MAPT
SCHEMBL6279196 0.78 CDK2 (0.60) CDK2CDK5CCNE1ALDH1A1MAPT
SCHEMBL6282655 0.77 CDK2 (0.78) CDK2CDK5CCNE1ALDH1A1MAPT
SCHEMBL6284915 0.77 CDK2 (0.78) CDK2CDK5CCNE1ALDH1A1MAPT
SCHEMBL6285271 0.77 CDK2 (0.78) CDK2CDK5CCNE1ALDH1A1MAPT
SCHEMBL6327485 0.76 CDK2 (0.61) CDK2CDK5CCNE1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US claimed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US claimed
US-6863647-B2 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2005-03-08 US disclosed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CDK2 3/4885CDK5 129/4885CCNE1 83/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CDK2 3/4885CDK5 129/4885CCNE1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.